<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623453</url>
  </required_header>
  <id_info>
    <org_study_id>ANTG-ASC-211</org_study_id>
    <nct_id>NCT01623453</nct_id>
  </id_info>
  <brief_title>Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)</brief_title>
  <acronym>ANTG</acronym>
  <official_title>A Follow-up Study to Evaluate the Sustained Healing Effect the Patients Who Showed Complete Closure of Fistula the Previous ANTG-ASC-210 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open follow-up clinical trial to evaluate a sustained efficacy and safety of
      ANTG-ASC injection for 4 months (6 months after final dose injection) after Phase II clinical
      trial.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting subjects
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Sustained efficacy of complete closure of fistula</measure>
    <time_frame>Month 4</time_frame>
    <description>Proportion of patients with completely closed of fistula (Month 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with sustained efficacy of closure of fistula</measure>
    <time_frame>Month 2, 4</time_frame>
    <description>Proportion of patients with completely closed of fistula (Month 2)
Proportion of patients with more than 50% closed of fistula (Month 2, 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Fecal Incontinence Score</measure>
    <time_frame>Month 4</time_frame>
    <description>Evaluation of Fecal Incontinence Score (Wexner Score, Cleveland Clinic Continence Scoring System)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of Investigator's satisfaction</measure>
    <time_frame>Month 2, 4</time_frame>
    <description>Grade of Investigator's satisfaction (Month 2, 4)
very satisfied
satisfied
moderately satisfied
dissatisfied
very dissatisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of systemic tolerance and physical examinations</measure>
    <time_frame>Month 2, 4</time_frame>
    <description>systemic tolerance (Month 4) (Biochemistry: Albumin, Alkaline phosphatase, ALT, AST, Bilirubin, Calcium, Chloride, Bicarbonate, Creatinine, Glucose, LDH, Potassium, Sodium, Total protein, Urea nitrogen(BUN), Uric acid / Hematology: Hemoglobin, Hematocrit, Reticulocyte count, complete blood cell count with differential, platelet count, WBC with differential count, ESR, PT/APTT)
Physical examination
Pregnancy testing (Month 4)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Perianal Fistula</condition>
  <condition>Primary; Complex</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <description>Group1. Low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <description>Group2. High dose group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose derived stem cells(low dose group)</intervention_name>
    <description>low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.</description>
    <arm_group_label>Low dose group</arm_group_label>
    <other_name>mesenchymal stem cell, ANTG-ASC, adipose derived stem cell</other_name>
    <other_name>Group 1: low dose group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose derived stem cells(high dose group)</intervention_name>
    <description>high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.</description>
    <arm_group_label>High dose group</arm_group_label>
    <other_name>mesenchymal stem cell, ANTG-ASC, adipose derived stem cell</other_name>
    <other_name>Group 2: high dose group</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        â€¢ the patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patients who have participated in ANTG-ASC-210 clinical trial

          -  the patients with complete closure at week 8 after last injection in ANTG-ASC-210
             trials

          -  the patients who submit written informed consents and is able to obey requirements of
             trials

        Exclusion Criteria:

          -  a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases

          -  a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue

          -  a patient who has an autoimmune disease

          -  a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C
             virus (HCV) or human immunodeficiency virus (HIV)

          -  a patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis
             of anus and rectum)

          -  a patient who is pregnant or breast feeding

          -  a patient who is not willing to use effective contraceptive methods during the study

          -  a patient who has inflammatory Bowel disease

          -  a patient who is sensitive to fibrin glue

          -  a patient who have a clinically relevant history of abuse of alcohol or drugs,
             habitual smoker (who smoked more than 20 cigarettes a day)

          -  a patient who is not able to understand the objective of this study or to comply with
             the study requirements

          -  a patient who is considered to have a significant disease which can impact the study
             by investigator

          -  a patient who is considered not suitable for the study by investigator

          -  a patient who had a history of surgery for malignant tumor within the last five years
             (except carcinoma in situ)

          -  a patient who has multisystemic wasting syndrome (such as tuberculosis, Diabetes,
             Thyroid disorders, tumor, etc.)

          -  a patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid,
             cytotoxic chemotherapy, anticoagulants, etc.) during long-term
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KJ Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DS Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daehang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaeHang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>crohn's disease</keyword>
  <keyword>fistula</keyword>
  <keyword>complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

